ClinicalTrials.gg
CompletedNCT03487107Updated Mar 18, 2020

Phase 3 Study of Yimitasvir Phosphate Capsules

A Phase 3 interventional study of SOF and DAG181 in Chronic HCV Infection, sponsored by Sunshine Lake Pharma Co., Ltd.. Completed at 35 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-18.

Sponsored by Sunshine Lake Pharma Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
362
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The safety, tolerability and antiviral activity of DAG181/SOF in treatment-naive and treatment-experienced patients with chronic hepatitis C virus (HCV) genotype 1 infection.

Read the detailed description

A phase III, multicenter, single-arm, open-label study to assess the safety, tolerability and antiviral activity of DAG181/SOF combination for 12 weeks in adult subjects with chronic genotype 1 HCV infection.

Approximately 360 HCV genotype 1 subjects without cirrhosis will be enrolled, treatment-experienced subjects are ≤20%. All subjects will receive DAG181 100 mg/ SOF 400 mg once daily for 12 weeks,with subsequent observation for 24 weeks after cessation of treatment.

02

Conditions studied

  • Chronic HCV Infection

Keywords

  • Chronic Genotype 1 HCV Infection
03

In context

Lead sponsor

Sunshine Lake Pharma Co., Ltd. is the lead sponsor of 83 studies on the registry; 13 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to provide written ;
  2. Male or female, age≥18 years;
  3. A female subject is eligible to enter the study if it is confirmed that she is:

    1. Of non- (i.e., women who have had a hysterectomy, have both ovaries removed or medically documented ovarian failure, or are -women > 50 years of age with cessation (for≥12 months) of previously occurring menses), or
    2. Of childbearing potential (Women≤50 years of age with amenorrhea will be considered to be of childbearing potential). These women must have a negative serum pregnancy test at screening and negative urine pregnancy test at baseline before first dose of study drugs, and must use specific methods from screening until 90 days after last dose of study drugs, such as complete abstinence from intercourse, vaginal ring, cervical cap or contraceptive diaphragm, IUD, etc.
  4. All male subjects must agree to consistently and correctly use specific contraceptive methods with their female partner from screening until 90 days after last dose of study drugs(except for surgical sterilization), such as complete abstinence from intercourse, condom, and their female partner use contraceptives , vaginal ring , cervical cap or contraceptive diaphragm, IUD, etc;
  5. Male subjects must agree to refrain from sperm donation from the date of screening until 90 days after the last dose of study drugs;
  6. Confirmation of chronic infection documented by either:

    1. A positive anti-HCV antibody test or positive HCV RNA or positive HCV genotyping test at least 6 months prior to the Baseline/Day 1 visit, or
    2. A liver performed prior to the Baseline/Day 1 visit with evidence of chronic HCV infection.
  7. Serological detection of anti-HCV antibodies was positive at screening;
  8. HCV RNA≥1×104 IU/mL at Screening;
  9. HCV genotype 1a, 1b, or mixed 1a/1b at screening as determined by the Central Laboratory;
  10. Classification as treatment naive or treatment experienced;
  11. Absence of cirrhosis.

Exclusion criteria

Exclusion Criteria:

  1. Investigator assessed subjects have other abnormalities (other than ), such as uncontrollable heart disease, respiratory, gastrointestinal, blood, nervous or other medical disorders, which may interfere with treatment, assessment, or compliance with the protocol;
  2. Laboratory results outside of acceptable ranges at Screening;
  3. serology test results were positive at Screening;
  4. antibody test results were positive at Screening;
  5. Prior exposure to approved or experimental HCV-specific direct-acting antiviral agent;
  6. Pregnant female or male with pregnant female partner.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
362 participants (actual)

Study arms

  • Experimental
    SOF 400 mg+DAG181 100 mg

    Patients with genotype 1 HCV infection without cirrhosis will receive SOF 400 mg+DAG181 100 mg for 12 weeks.

    Drug: SOF · Drug: DAG181

Interventions

  • DrugSOF

    400 mg tablet administered orally once daily

    Also known as: sofosbuvir, Sovaldi®

  • DrugDAG181

    100 mg capsule administered orally once daily

    Also known as: Yimitasvir

06

What researchers measure

Primary outcomes

  1. Percentage of subjects with sustained virologic response 12 weeks after discontinuation of therapy(SVR12)

    SVR12 is defined as HCV RNA \< the lower limit of quantitation (LLOQ) at 12 weeks after discontinuation of therapy

    Time frame: Posttreatment Week 12

  2. Safety and tolerability were evaluated based on adverse events

    Collecting all adverse events during the whole study

    Time frame: Up to posttreatment week 24

Secondary outcomes

  1. Percentage of subjects with sustained virologic response 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)

    SVR4 and SVR24 were defined as HCV RNA \< the lower limit of quantitation (LLOQ) at 4 and 24 weeks after discontinuation of therapy, respectively.

    Time frame: Posttreatment Weeks 4 and 24

  2. HCV RNA change from baseline

    the quantification of HCV RNA during and after treatment compared with baseline

    Time frame: Up to posttreatment week 24

  3. Percentage of subjects with virologic failure

    1. On-treatment virologic failure: 1. confirmed HCV RNA ≥ the lower limit of quantitation (LLOQ) after having previously had HCV RNA \<the lower limit of quantitation (LLOQ) while on treatment; 2. confirmed ≥ 1 log10 IU/mL increase in HCV RNA from nadir while on treatment; 3. HCV RNA persistently ≥the lower limit of quantitation (LLOQ) through 8 weeks of treatment. 2. Virologic relapse: 1. Confirmed HCV RNA ≥the lower limit of quantitation (LLOQ) during the posttreatment period having achieved HCV RNA \<the lower limit of quantitation (LLOQ) at last on-treatment visit.

    Time frame: Up to posttreatment week 24

  4. Percentage of subjects with viral resistance to DAG181 and/or SOF

    Monitoring HCV virus resistance at baseline, during and after treatment

    Time frame: Up to posttreatment week 24

07

Study locations

35 sites
  • Beijing Ditan Hospital Affiliated to Capital Medical University
    Beijing, Beijing 100020, China
  • Peking University First Hospital
    Beijing, Beijing 100034, China
  • Peking University People's Hospital
    Beijing, Beijing 100044, China
  • Beijing Friendship Hospital,Capital Medical University
    Beijing, Beijing 100050, China
  • Beijing YouAn Hospital,Capital Medical University
    Beijing, Beijing 100069, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian 350005, China
  • Mengchao Hepatobiliary Hospital of Fujian Medical University
    Fuzhou, Fujian 350025, China
  • The First Hospital of Lanzhou University
    Lanzhou, Gansu 730000, China
  • Guangzhou Eighth People's Hospital
    Guangzhou, Guangdong 510060, China
  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangdong 510515, China
  • Hainan General Hospital
    Haikou, Hainan 570311, China
  • The Third Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050051, China
  • The First Affiliated Hospital of Xinxiang Medical University
    Xinxiang, Henan 453100, China
  • People's Hospital of Zhengzhou
    Zhengzhou, Henan 450003, China
  • The Central Hospital of Wuhan
    Wuhan, Hubei 430010, China
  • Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Tongji Hospital Affiliated to Tongji Medical College of Huazhong University Science & Technology
    Wuhan, Hubei 430030, China
  • Renmin Hospital of Wuhan University
    Wuhan, Hubei 430060, China
  • Hunan Provincial People's Hospital
    Changsha, Hunan 410000, China
  • Xiangya Hospital, Central South University
    Changsha, Hunan 410008, China
  • The People's Liberation Army No.81 Hospital
    Nanjing, Jiangsu 210002, China
  • The Second Hospital of Nanjing
    Nanjing, Jiangsu 210003, China
  • The Fifth People's Hospital of Wuxi
    Wuxi, Jiangsu 214073, China
  • The Affiliated Hospital of Xuzhou Medical Hospital
    Xuzhou, Jiangsu 221002, China
  • The Third People's Hospital of Zhenjiang
    Zhenjiang, Jiangsu 212004, China
  • The First Affiliated Hospital of NanChang University
    Nanchang, Jiangxi 330006, China
  • The First Hospital of Jilin University
    Chang Chun, Jilin 130021, China
  • The Sixth People's Hospital of Shenyang
    Shenyang, Liaoning 110006, China
  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai 200020, China
  • Shanghai Public Health Clinical Center
    Shanghai, Shanghai 201500, China
  • Tangdu Hospital
    Xi'an, Shanxi 710038, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shanxi 710061, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan 610072, China
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang 325000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Mar 2019, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2018
First posted
Apr 3, 2018
StartActual
Apr 17, 2018
Primary completionActual
Mar 28, 2019
CompletionActual
Jun 25, 2019
Last update
Mar 18, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03487107
Responsible party
Sponsor
First posted
Apr 3, 2018
Start date
Apr 17, 2018
Primary completion
Mar 28, 2019
Completion
Jun 25, 2019
Last update
Mar 18, 2020

Study contacts

Lai Wei, Doctor
study chair · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Yimitasvir

Start the discussion